Review Outlines Reciprocal Signaling Framework Between Multikingdom Gut Microbiome and Immune Aging

A peer-reviewed analysis proposes that therapeutic strategies for immunosenescence should shift from trying to restore a youthful gut microbiome toward targeting specific host-sensing pathways and microbial functional outputs.

A review paper published in Ageing Research Reviews by researchers Jiang et al. examines how multikingdom gut microbiome remodeling—spanning the bacteriome, mycobiome, virome, and archaeome—intersects with distinct trajectories of immune aging.

The authors outline four interconnected host-microbiome signaling processes: microbial signal generation, tissue access and compartmentalization, host sensing, and cell-specific interpretation.

The paper highlights that causal evidence is most mature for bacteriome-associated mechanisms in experimental models, while aging-specific mechanistic evidence for the mycobiome, virome, and archaeome remains comparatively limited.

The relationship is presented as reciprocal, with intrinsic immune and tissue aging actively reshaping microbial ecology and functional capacity, rather than the microbiome acting as an autonomous driver of immunosenescence.

This framework challenges the simplistic view of gut dysbiosis as a unidirectional cause of immune decline, suggesting instead a complex feedback loop.

By identifying host sensing and cell-specific interpretation as key nodes, the research suggests that targeting host-response pathways may yield more predictable therapeutic outcomes than attempting to remodel a highly variable aged microbiome.

The review's emphasis on host-sensing pathways and specific microbiome-associated functions validates drug discovery platforms targeting defined metabolic and immune receptors over general gut health formulations.

It points to a significant knowledge gap and opportunity in the longevity market, noting the lack of mechanistic data for non-bacterial kingdoms (mycobiome, virome, and archaeome) during aging.

Translational focus shifts toward preclinical and clinical trials evaluating specific microbial metabolites or host-receptor agonists that modulate immunosenescence phenotypes.